68 results
6-K
EX-99.1
CLYYF
Celyad Oncology SA
21 Nov 23
Current report (foreign)
8:06am
measures
The Company will grant access to the meeting room only to the extent permitted by the authorities on the meeting’s date. The Company
6-K
EX-99.1
CLYYF
Celyad Oncology SA
27 Oct 23
Current report (foreign)
1:45pm
, but only with a consultation right.
PARTICIPATION IN THE MEETING
Covid-19 measures
The Company will grant access to the meeting room only
6-K
EX-99.1
CLYYF
Celyad Oncology SA
22 Sep 23
Current report (foreign)
6:06am
right.
PARTICIPATION IN THE MEETING
Covid-19 measures
The Company will grant access to the meeting room only to the extent permitted by the authorities
6-K
EX-99.2
CLYYF
Celyad Oncology SA
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
.
The development of allogeneic,‘off-the-shelf’
CART-
cells allows to overcome many of these limitations, contributing to scalability and direct access to CART
6-K
EX-99.1
CLYYF
Celyad Oncology SA
5 Sep 23
Celyad Oncology Reports First Half 2023 Financial
6:12am
recent changes and upcoming milestones.
Participants may access the conference call by dialing +1-877-407-9716 or +1-201-493-6779 (United States … , International), +32 (0) 800-73-904 (Belgium Fixed) or +32 (0) 800-73-566 (Belgium Mobile). Participants may ask for instant telephone access to the event
6-K
EX-10.3
rr4e a2w5
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.2
pb9mbvqk 2l
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.1
b9j26nd vmt
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-10.4
t63d bwn4sv6951d
25 Aug 23
Celyad Oncology receives approximately EUR 9.8m in private placement commitments from historical shareholders
6:07am
6-K
EX-99.1
uqxfb09mv94cjtbywd
4 Apr 23
Current report (foreign)
7:45am
6-K
EX-99.1
7bvjx0hrz4zg62wgj
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-99.2
26ss4
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
6-K
EX-99.1
amxt0v2ms8p5x9r05du
6 May 22
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
5:23pm
6-K
EX-99.1
bzzdf04il6w7yk5jag
24 Mar 22
Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
5:45pm
6-K
EX-99.1
wy5ysm y8
12 Jan 22
Celyad Oncology Provides Outlook for 2022
6:06am
6-K
jlcs74fudxb4
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-99.1
unt353n511cuw5r6
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-10.2
nhhon ujwz89e0coow
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am
6-K
EX-10.1
wbfl2
3 Dec 21
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
9:19am